(IFF) International Flavors - Overview
Stock: Flavors, Fragrances, Enzymes, Excipients
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 2.32% |
| Yield on Cost 5y | 1.44% |
| Yield CAGR 5y | -15.38% |
| Payout Consistency | 97.3% |
| Payout Ratio | 47.1% |
| Risk 5d forecast | |
|---|---|
| Volatility | 26.4% |
| Relative Tail Risk | -7.49% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.38 |
| Alpha | -23.70 |
| Character TTM | |
|---|---|
| Beta | 0.732 |
| Beta Downside | 0.519 |
| Drawdowns 3y | |
|---|---|
| Max DD | 42.62% |
| CAGR/Max DD | -0.12 |
Description: IFF International Flavors January 02, 2026
International Flavors & Fragrances Inc. (NYSE:IFF) is a global specialty-chemicals company that develops and sells ingredients for food, beverage, health & biosciences, fragrance, and pharmaceutical markets. Its operations are organized into four reporting segments: Nourish (natural-based food ingredients and flavors), Health & Biosciences (enzymes, cultures, animal nutrition, and grain-processing solutions), Scent (fragrance compounds and ingredients), and Pharma Solutions (cellulosic and seaweed-derived excipients). The firm, founded in 1909, is headquartered in New York and serves customers across the United States, Europe, and the rest of the world.
In FY 2023 IFF reported revenue of roughly $11.6 billion, a 4 % year-over-year increase driven primarily by the Nourish segment’s plant-based protein portfolio and the Scent segment’s premium fragrance demand. Adjusted EBITDA margin held steady near 13 %, while free cash flow conversion remained above 80 %, reflecting strong pricing power and efficient capital allocation. The company’s balance sheet is solid, with net debt-to-EBITDA ≈ 1.2×, indicating low financial risk.
Key economic and sector drivers for IFF include: (1) the accelerating consumer shift toward clean-label, plant-based, and functional foods, which fuels demand for soy, pea protein, natural sweeteners, and antimicrobial ingredients; (2) rising global fragrance spending, especially in emerging markets where premium personal-care products are gaining market share; and (3) regulatory pressure on synthetic additives, prompting manufacturers to source natural alternatives-a trend that aligns with IFF’s R&D pipeline and sustainability commitments.
For a deeper dive into IFF’s valuation metrics and scenario analysis, you may find ValueRay’s research platform useful.
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income: -412.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA -1.80 > 1.0 |
| NWC/Revenue: 16.32% < 20% (prev 45.59%; Δ -29.27% < -1%) |
| CFO/TA 0.03 > 3% & CFO 900.0m > Net Income -412.0m |
| Net Debt (6.52b) to EBITDA (698.0m): 9.35 < 3 |
| Current Ratio: 1.44 > 1.5 & < 3 |
| Outstanding Shares: last quarter (257.0m) vs 12m ago 0.0% < -2% |
| Gross Margin: 36.38% > 18% (prev 0.35%; Δ 3603 % > 0.5%) |
| Asset Turnover: 39.76% > 50% (prev 38.14%; Δ 1.61% > 0%) |
| Interest Coverage Ratio: -1.08 > 6 (EBITDA TTM 698.0m / Interest Expense TTM 249.0m) |
Altman Z'' -0.46
| A: 0.07 (Total Current Assets 5.88b - Total Current Liabilities 4.07b) / Total Assets 25.77b |
| B: -0.13 (Retained Earnings -3.35b / Total Assets 25.77b) |
| C: -0.01 (EBIT TTM -270.0m / Avg Total Assets 27.85b) |
| D: -0.42 (Book Value of Equity -4.77b / Total Liabilities 11.49b) |
| Altman-Z'' Score: -0.46 = B |
Beneish M -3.11
| DSRI: 1.00 (Receivables 1.87b/1.94b, Revenue 11.07b/11.42b) |
| GMI: 0.96 (GM 36.38% / 35.07%) |
| AQI: 1.05 (AQ_t 0.60 / AQ_t-1 0.57) |
| SGI: 0.97 (Revenue 11.07b / 11.42b) |
| TATA: -0.05 (NI -412.0m - CFO 900.0m) / TA 25.77b) |
| Beneish M-Score: -3.11 (Cap -4..+1) = AA |
What is the price of IFF shares?
Over the past week, the price has changed by +7.18%, over one month by +8.64%, over three months by +19.78% and over the past year by -10.61%.
Is IFF a buy, sell or hold?
- StrongBuy: 10
- Buy: 7
- Hold: 4
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the IFF price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 82.4 | 10.1% |
| Analysts Target Price | 82.4 | 10.1% |
| ValueRay Target Price | 79.1 | 5.7% |
IFF Fundamental Data Overview February 05, 2026
P/S = 1.6291
P/B = 1.2554
P/EG = 2.384
Revenue TTM = 11.07b USD
EBIT TTM = -270.0m USD
EBITDA TTM = 698.0m USD
Long Term Debt = 4.74b USD (from longTermDebt, last quarter)
Short Term Debt = 1.31b USD (from shortTermDebt, last quarter)
Debt = 7.14b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.52b USD (from netDebt column, last quarter)
Enterprise Value = 24.56b USD (18.04b + Debt 7.14b - CCE 621.0m)
Interest Coverage Ratio = -1.08 (Ebit TTM -270.0m / Interest Expense TTM 249.0m)
EV/FCF = 73.98x (Enterprise Value 24.56b / FCF TTM 332.0m)
FCF Yield = 1.35% (FCF TTM 332.0m / Enterprise Value 24.56b)
FCF Margin = 3.00% (FCF TTM 332.0m / Revenue TTM 11.07b)
Net Margin = -3.72% (Net Income TTM -412.0m / Revenue TTM 11.07b)
Gross Margin = 36.38% ((Revenue TTM 11.07b - Cost of Revenue TTM 7.04b) / Revenue TTM)
Gross Margin QoQ = 36.49% (prev 37.26%)
Tobins Q-Ratio = 0.95 (Enterprise Value 24.56b / Total Assets 25.77b)
Interest Expense / Debt = 0.67% (Interest Expense 48.0m / Debt 7.14b)
Taxrate = 26.79% (15.0m / 56.0m)
NOPAT = -197.7m (EBIT -270.0m * (1 - 26.79%)) [loss with tax shield]
Current Ratio = 1.44 (Total Current Assets 5.88b / Total Current Liabilities 4.07b)
Debt / Equity = 0.50 (Debt 7.14b / totalStockholderEquity, last quarter 14.24b)
Debt / EBITDA = 9.35 (Net Debt 6.52b / EBITDA 698.0m)
Debt / FCF = 19.65 (Net Debt 6.52b / FCF TTM 332.0m)
Total Stockholder Equity = 13.92b (last 4 quarters mean from totalStockholderEquity)
RoA = -1.48% (Net Income -412.0m / Total Assets 25.77b)
RoE = -2.96% (Net Income TTM -412.0m / Total Stockholder Equity 13.92b)
RoCE = -1.45% (EBIT -270.0m / Capital Employed (Equity 13.92b + L.T.Debt 4.74b))
RoIC = -0.92% (negative operating profit) (NOPAT -197.7m / Invested Capital 21.55b)
WACC = 6.31% (E(18.04b)/V(25.18b) * Re(8.61%) + D(7.14b)/V(25.18b) * Rd(0.67%) * (1-Tc(0.27)))
Discount Rate = 8.61% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.39%
[DCF Debug] Terminal Value 78.61% ; FCFF base≈569.2m ; Y1≈373.6m ; Y5≈170.5m
Fair Price DCF = N/A (negative equity: EV 4.82b - Net Debt 6.52b = -1.70b; debt exceeds intrinsic value)
EPS Correlation: -54.19 | EPS CAGR: -53.55% | SUE: -3.92 | # QB: 0
Revenue Correlation: -77.22 | Revenue CAGR: -3.09% | SUE: 1.54 | # QB: 2
EPS next Quarter (2026-03-31): EPS=1.17 | Chg30d=+0.017 | Revisions Net=+2 | Analysts=9
EPS next Year (2026-12-31): EPS=4.47 | Chg30d=+0.002 | Revisions Net=+2 | Growth EPS=+5.0% | Growth Revenue=-2.0%